Status:

NOT_YET_RECRUITING

Preemptive Treatment With Acyclovir in Intubated and Mechanically Ventilated Patients With Herpes (PTH2)

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Invasive Mechanical Ventilation

HSV Throat Reactivation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This research aims to assess the interest of preemptive treatment with Acyclovir in mechanically ventilated patients with reactivation of Herpes simplex (HSV) in the throat and failure of one organ or...

Detailed Description

Herpes simplex virus (HSV) reactivations are frequent in intensive care unit (ICU) patients receiving invasive mechanical ventilation. HSV reactivation first occurs in the throat (incidence up to 20-5...

Eligibility Criteria

Inclusion

  • aged ≥ 18 year-old
  • invasive mechanical ventilation(MV) for 96 hours and planned to last for at least 48 hours longer
  • HSV reactivation in the throat (qualitative PCR positive for HSV on a throat swab)
  • Presence of 1 or less organ failure; organ failure being defined as a corresponding-organ SOFA score of 3 or 4 (for example, renal failure will be defined as a renal SOFA score of 3 or 4)
  • Effective contraception for patients of childbearing age, throughout the treatment period
  • Written consent from the patient, from a close relative or from the person of trust previously appointed (or inclusion procedure in emergency situations)
  • Under social security cover

Exclusion

  • Hypersensitivity to acyclovir and excipient
  • Pregnant or breastfeeding (controlled by a blood pregnancy test)
  • Patient who received an antiviral drug active against HSV (acyclovir, valacyclovir, gancyclovir, valgancyclovir, foscavir, cidofovir) in the previous 30 days
  • Duration of ventilation before randomization \>15 days
  • Neutropenia, defined by an absolute neutrophils count \< 1,000/mm3
  • Solid organ or bone-marrow transplant
  • Immunosuppressive treatment (including steroids at a dose \>0.5 mg/kg/day of prednisone or equivalent for \>1 month)
  • HIV infection
  • Moribund, defined by a Simplified Acute Physiology Score (SAPS) II score at inclusion \>75 points
  • Decision of withholding/withdrawing care

Key Trial Info

Start Date :

March 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2027

Estimated Enrollment :

246 Patients enrolled

Trial Details

Trial ID

NCT06217406

Start Date

March 1 2024

End Date

March 1 2027

Last Update

January 22 2024

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.